Disseminated breast cancer cells prior to and after high-dose therapy.
暂无分享,去创建一个
N. Kröger | A. Zander | F. Jänicke | R. Hornung | W. Krüger | F. Tögel | K. Gutensohn | F. Gieseking | H. Renges | A. Badbaran | R. Jung
[1] N. Kröger,et al. Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells. , 2001, Journal of hematotherapy & stem cell research.
[2] N. Kröger,et al. Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells. , 2001, Journal of hematotherapy & stem cell research.
[3] N. Kröger,et al. Immunomagnetic tumor cell selection—implications for the detection of disseminated cancer cells , 2000, Transfusion.
[4] H Sommer,et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] N. Kröger,et al. Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer , 1999, Medical oncology.
[6] H. Lazarus,et al. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] I. Funke,et al. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Braun,et al. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.
[9] N. Kröger,et al. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study. , 1996, Bone marrow transplantation.
[10] H. Allgayer,et al. Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer , 1995, Nature Medicine.
[11] S. Heimfeld,et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. , 1994, Blood.
[12] L. Kanz,et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments] , 1994 .
[13] N. Davidson,et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. , 1993, Blood.
[14] G. Rosner,et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Nienhuis,et al. Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia, or metastatic breast cancer. , 1993, Human gene therapy.
[16] M L Lesser,et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.